Janux Therapeutics, Inc. (JANX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$16.30−$0.3800 (−2.28%) on the dayAs of the close; data may be delayed.
JANX price, last 12 months
Key stats
- Previous close
- $16.68
- Open
- $16.62
- Day range
- $16.21 – $16.70
- 52-week range
- $12.12 – $35.34
- Volume
- 575.3K
- Avg volume (20 days)
- 1M
- Market cap
- $996.5M
Performance
1W−1.8%
1M−13.7%
3M+9.1%
6M+19.6%
YTD+18.1%
1Y−28.6%
vs S&P 500, 1Y−45.4 pts
Technicals and fundamentals
About Janux Therapeutics, Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $996.5M